— Know what they know.
Not Investment Advice

IPSC NASDAQ

Century Therapeutics, Inc.
1W: -8.4% 1M: -27.5% 3M: -36.2% YTD: +53.8% 1Y: +206.1% 3Y: -24.3% 5Y: -93.4%
$1.53
-0.08 (-4.97%)
 
Weekly Expected Move ±6.8%
$1 $1 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 26 · $277.0M mcap · 101M float · 0.981% daily turnover · Short 53% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
27.1 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -60.0%  ·  5Y Avg: -61.8%
Cost Advantage
23
Intangibles
25
Switching Cost
26
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. IPSC has No discernible competitive edge (27.1/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. Negative ROIC of -60.0% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$0
Low
$3
Avg Target
$3
High
Based on 2 analyst ratings (12 mo)
Analyst Recommendations
Strong Buy: 0Buy: 7Hold: 2Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$3.00
Analysts2
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-03-13 Leerink Partners Daina Graybosch $27 $2 -25 -20.6% $2.52
2026-01-20 Piper Sandler — $9 $4 -5 +84.3% $2.17
2024-11-06 H.C. Wainwright Mitchell Kapoor $25 $5 -20 +259.7% $1.39
2024-04-12 Piper Sandler Edward Tenthoff $14 $9 -5 +122.2% $4.05
2023-01-05 Piper Sandler Edward Tenthoff Initiated $14 — +189.3% $4.84
2022-12-27 Chardan Capital Geulah Livshits Initiated $19 — +235.1% $5.67
2022-11-14 H.C. Wainwright — Initiated $25 — +127.3% $11.00
2022-04-29 Leerink Partners — Initiated $27 — +124.4% $12.03

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C-
Oct 02, 2026
DCF
1
ROE
1
ROA
1
D/E
2
P/E
1
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. IPSC receives an overall rating of C-. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (2/5), P/E (1/5).
Rating Change History
DateFromTo
2026-10-01 C C-
2026-05-19 C- C
2026-05-14 C C-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+
Profitability
—
Balance Sheet
82
Earnings Quality
54
Growth
12
Value
39
Momentum
20
Safety
15
Cash Flow
—

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
0.59
Distress Zone
Piotroski F-Score
2/9
✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗ ✗
Beneish M-Score
—
—
Ohlson O-Score
-4.20
Bankruptcy prob: 1.5%
Low Risk
Credit Rating
BB+
Score: 48.8/100
Trend: Improving
Earnings Quality
—
OCF/NI: 0.79x
Accruals: -8.1%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. IPSC scores 0.59, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. IPSC scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. IPSC's implied 1.5% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. IPSC receives an estimated rating of BB+ (score: 48.8/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-1.47x
PEG
0.00x
P/S
0.00x
P/B
1.36x
P/FCF
-5.69x
P/OCF
—
EV/EBITDA
-4.18x
EV/Revenue
—
EV/EBIT
-3.81x
EV/FCF
-4.73x
Earnings Yield
-21.78%
FCF Yield
-17.56%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. IPSC currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.999
NI / EBT
×
Interest Burden
1.000
EBT / EBIT
×
EBIT Margin
—
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.293
Assets / Equity
=
ROE
-49.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. IPSC's ROE of -49.7% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1329 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$1.53
Median 1Y
$0.66
5th Pctile
$0.18
95th Pctile
$2.44
Ann. Volatility
81.0%
25th–75th percentile 5th–95th percentile Median path Historical

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Brent Pfeiffenberger, Pharm.D.,
President, Chief Executive Officer and Chairman of the Board
$640,625 $1,869,609 $2,381,022
Chad Cowan ,
Ph.D. , Chief Scientific Officer
$559,532 $398,329 $1,167,015
Adrienne Farid, Ph.D.,
Former Chief Development Officer
$333,348 $71,120 $989,403
Gregory Russotti, Ph.D.,
Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer
$559,650 $71,120 $912,320

CEO Pay Ratio

8:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $2,381,022
Avg Employee Cost (SGA/emp): $307,731
Employees: 78

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
78
-44.3% YoY
Revenue / Employee
$1,399,538
Rev: $109,164,000
Profit / Employee
$-122,821
NI: $-9,580,000
SGA / Employee
$307,731
Avg labor cost proxy
R&D / Employee
$1,226,500
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -11.7% -19.6% -29.7% -30.5% -33.8% -37.5% -37.6% -41.9% -46.9% -56.1% -58.7% -55.9% -62.6% -73.1% -10.5% -10.8% -14.2% -6.0% -42.7% -49.7% -49.65%
ROA -10.5% -17.7% -20.9% -23.9% -26.0% -28.3% -24.8% -26.7% -28.4% -32.3% -33.2% -31.5% -33.0% -35.5% -6.6% -6.6% -8.4% -3.3% -33.6% -38.4% -38.41%
ROIC -25.2% -30.6% -1.8% -4.7% -4.7% -2.9% -1.3% -78.4% -1.1% -1.9% -3.6% -1.4% -2.2% -4.2% -20.2% -24.1% -23.7% -9.1% -48.6% -60.0% -59.98%
ROCE -10.8% -18.1% -21.5% -23.8% -26.0% -28.4% -28.5% -31.0% -33.1% -36.2% -37.8% -31.4% -33.7% -57.3% -7.5% -8.9% -12.2% -5.9% -34.5% -40.4% -40.40%
Gross Margin — — 1.0% 1.0% 1.0% -5.5% -26.2% 1.0% -153.0% -82.2% 1.0% 1.0% 1.0% 1.0% 1.0% — — — — — —
Operating Margin — — -35.4% -22.5% -14.3% -63.9% -18.7% -354.3% -240.7% -163.3% -36.6% -45.1% -44.0% -8.9% 67.9% — — — — — —
Net Margin — — -35.5% -22.2% -13.8% -60.8% -18.2% -336.3% -221.1% -147.0% -32.8% -40.5% -39.5% -8.6% 70.1% — — — — — —
EBITDA Margin — — -34.1% -20.8% -12.4% -53.5% -16.0% -292.6% -191.1% -101.0% -32.8% -36.0% -35.3% -7.4% 70.9% — — — — — —
FCF Margin — — -25.7% -13.9% -6.1% -3.2% -22.8% -26.6% -41.8% -45.7% -72.0% -50.2% -42.1% -16.7% -99.3% -1.0% -99.4% -95.9% — — —
OCF Margin — — 18.8% 5.2% 2.7% 2.7% -17.4% -20.9% -34.2% -39.5% -65.2% -47.7% -41.8% -16.7% -99.7% -1.0% -98.8% -95.2% — — —
ROE 3Y Avg snapshot only -39.17%
ROE 5Y Avg snapshot only -40.61%
ROA 3Y Avg snapshot only -25.99%
ROIC 3Y Avg snapshot only -51.45%
ROIC Economic snapshot only -33.08%
Cash ROA snapshot only -30.22%
Cash ROIC snapshot only -58.90%
CROIC snapshot only -60.12%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -27.81 -11.15 -6.25 -3.95 -4.50 -2.29 -1.63 -1.47 -0.92 -1.45 -1.95 -1.59 -1.12 -0.63 -1.87 -2.07 -1.63 -8.99 -1.81 -4.59 -1.471
P/S Ratio — — 678.90 197.45 122.56 57.56 34.70 41.02 47.79 88.95 190.07 102.51 53.95 12.05 0.36 0.42 0.38 0.79 — — 0.000
P/B Ratio 3.24 2.18 1.86 1.35 1.74 0.99 0.73 0.76 0.54 1.08 1.46 0.94 0.74 0.49 0.17 0.23 0.24 0.54 0.74 2.17 1.355
P/FCF -19.91 -7.86 -26.39 -14.20 -20.15 -18.08 -1.52 -1.55 -1.14 -1.95 -2.64 -2.04 -1.28 -0.72 -0.36 -0.42 -0.38 -0.82 -2.04 -5.69 -5.695
P/OCF — — 36.04 37.67 45.48 21.30 — — — — — — — — — — — — — — —
EV/EBITDA -23.59 -9.17 -3.52 -1.27 -2.23 -0.27 -0.04 -0.65 0.03 -0.66 -1.02 -0.62 -0.01 0.49 7.73 5.17 3.15 11.68 -1.15 -4.18 -4.185
EV/Revenue — — 361.34 59.92 56.60 6.38 0.67 15.96 -1.22 33.22 83.83 33.94 0.49 -8.50 -0.62 -0.49 -0.39 0.12 — — —
EV/EBIT -22.63 -8.71 -3.36 -1.21 -2.10 -0.26 -0.03 -0.59 0.02 -0.60 -0.91 -0.56 -0.01 0.44 3.17 2.35 1.65 -1.04 -1.01 -3.81 -3.815
EV/FCF -15.99 -6.06 -14.04 -4.31 -9.31 -2.00 -0.03 -0.60 0.03 -0.73 -1.16 -0.68 -0.01 0.51 0.63 0.49 0.40 -0.12 -1.13 -4.73 -4.734
Earnings Yield -3.6% -9.0% -16.0% -25.3% -22.2% -43.8% -61.3% -67.8% -1.1% -68.7% -51.3% -62.8% -89.7% -1.6% -53.5% -48.3% -61.5% -11.1% -55.1% -21.8% -21.78%
FCF Yield -5.0% -12.7% -3.8% -7.0% -5.0% -5.5% -65.6% -64.7% -87.5% -51.3% -37.9% -49.0% -78.1% -1.4% -2.8% -2.4% -2.6% -1.2% -49.0% -17.6% -17.56%
PEG Ratio snapshot only 0.001
Price/Tangible Book snapshot only 2.544
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 15.12 14.57 16.62 17.79 13.44 10.72 9.24 8.42 8.50 9.92 12.44 10.62 10.39 1.50 11.70 10.72 6.25 5.97 10.25 8.28 8.280
Quick Ratio 15.12 14.57 16.62 17.79 13.44 10.72 9.24 8.42 8.50 9.92 12.44 10.62 10.39 1.50 11.70 10.72 6.25 5.97 10.25 8.28 8.280
Debt/Equity 0.06 0.06 0.06 0.12 0.14 0.16 0.19 0.17 0.22 0.26 0.26 0.25 0.28 0.33 0.22 0.25 0.25 0.27 0.18 0.15 0.149
Net Debt/Equity -0.64 -0.50 -0.87 -0.94 -0.93 -0.88 -0.72 -0.46 -0.56 -0.67 -0.82 -0.63 -0.73 -0.84 -0.47 -0.50 -0.50 -0.46 -0.33 -0.37 -0.366
Debt/Assets 0.05 0.06 0.05 0.08 0.09 0.10 0.11 0.10 0.12 0.13 0.13 0.14 0.14 0.15 0.17 0.18 0.18 0.19 0.15 0.12 0.121
Debt/EBITDA -0.54 -0.35 -0.23 -0.36 -0.40 -0.41 -0.46 -0.38 -0.42 -0.43 -0.41 -0.51 -0.49 -0.47 -5.70 -4.74 -3.16 40.53 -0.51 -0.35 -0.346
Net Debt/EBITDA 5.78 2.72 3.09 2.92 2.60 2.21 1.78 1.02 1.08 1.11 1.29 1.26 1.30 1.18 12.17 9.61 6.18 -68.42 0.91 0.85 0.850
Interest Coverage -76.00 -112.79 -114.65 -121.01 -119.65 -90.66 -80.28 -93.15 -130.87 -229.81 -924.68 — — — — — — — — — —
Equity Multiplier 1.11 1.10 1.42 1.49 1.55 1.61 1.65 1.69 1.81 1.95 1.96 1.88 1.99 2.19 1.31 1.36 1.39 1.41 1.23 1.24 1.235
Cash Ratio snapshot only 7.945
Cash to Debt snapshot only 3.457
FCF to Debt snapshot only -2.557
Defensive Interval snapshot only 413.5 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.02 0.35 0.33 0.36 0.38 0.00 0.00 0.000
Inventory Turnover — — — — — — — — — — — — — — — — — — — — —
Receivables Turnover 0.00 0.00 4.28 11.66 16.86 10.10 6.85 4.59 2.45 3.09 1.87 2.39 1.78 6.03 233.77 364.63 123.66 99.83 0.00 0.00 0.000
Payables Turnover 0.17 0.51 0.39 0.34 0.22 0.52 0.83 1.45 4.88 11.53 13.05 12.91 5.23 0.00 0.00 0.98 2.43 1.61 2.78 1.53 1.527
DSO — — 85 31 22 36 53 80 149 118 195 152 205 61 2 1 3 4 — — —
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 — — 0 0 0 0 0 0.0 days
DPO 2148 718 935 1089 1678 704 439 252 75 32 28 28 70 — — 374 150 226 131 239 239.0 days
Cash Conversion Cycle — — -849 -1058 -1656 -668 -386 -173 74 86 167 124 135 — — -373 -147 -223 — — —
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue — — — — — — 4.5% 86.0% -46.8% -57.0% -76.6% -55.3% 7.9% 1.9% 82.9% 54.9% 41.2% 15.6% -1.0% -1.0% -1.00%
Net Income — — — -4.3% -1.6% -69.0% -8.4% -3.5% -1.2% -4.4% -7.0% -3.5% -0.7% 7.4% 83.6% 82.3% 79.6% 92.4% -3.9% -3.7% -3.72%
EPS — — — -4.0% -1.4% -57.8% -5.5% -0.8% 1.3% -1.7% -0.7% 25.3% 29.3% 29.5% 88.1% 83.1% 80.0% 93.1% -3.9% -97.6% -97.64%
FCF — — — -17.2% 58.7% 84.9% -3.9% -2.6% -2.7% -5.2% 26.1% 15.4% -8.7% -8.0% -15.7% -11.6% 0.4% 5.1% 16.0% 22.6% 22.64%
EBITDA — — — -4.3% -1.5% -66.2% -3.1% 3.3% 5.2% 7.3% -0.3% 0.7% 1.6% -2.6% 91.8% 90.2% 87.2% 1.0% -9.3% -8.2% -8.22%
Op. Income — — — -4.3% -1.6% -74.2% -12.4% -7.8% -5.9% -9.5% -13.5% -10.0% -6.3% 5.7% 77.6% 77.9% 81.7% 92.8% -2.4% -2.5% -2.47%
OCF Growth snapshot only 24.43%
Asset Growth snapshot only 0.81%
Equity Growth snapshot only 10.69%
Debt Growth snapshot only -32.74%
Shares Change snapshot only 1.39%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y — — — — — — — — — — — — — — 3.8% 2.6% 1.9% 1.8% — — —
Revenue 5Y — — — — — — — — — — — — — — — — — — — — —
EPS 3Y — — — — — — — — — — — — — — — — — — — — —
EPS 5Y — — — — — — — — — — — — — — — — — — — — —
Net Income 3Y — — — — — — — — — — — — — — — — — — — — —
Net Income 5Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 3Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 5Y — — — — — — — — — — — — — — — — — — — — —
Gross Profit 3Y — — — — — — — — — — — — — — — — 2.4% 2.8% — — —
Gross Profit 5Y — — — — — — — — — — — — — — — — — — — — —
Op. Income 3Y — — — — — — — — — — — — — — — — — — — — —
Op. Income 5Y — — — — — — — — — — — — — — — — — — — — —
FCF 3Y — — — — — — — — — — — — — — — — — — — — —
FCF 5Y — — — — — — — — — — — — — — — — — — — — —
OCF 3Y — — — — — — — — — — — — — — — — — — — — —
OCF 5Y — — — — — — — — — — — — — — — — — — — — —
Assets 3Y — — — — — — — — — — — -5.6% -6.1% -6.9% -16.9% -18.8% -21.8% -22.8% -10.5% -11.7% -11.72%
Assets 5Y — — — — — — — — — — — — — — — — — — — -10.4% -10.35%
Equity 3Y — — — — — — — — — — — -20.8% -22.7% -25.9% -14.6% -16.3% -18.9% -19.3% -1.5% -2.1% -2.09%
Book Value 3Y — — — — — — — — — — — -31.0% -33.2% -34.4% -25.6% -26.8% -29.0% -29.3% -13.5% -35.3% -35.35%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability — — — — — — — 1.00 0.28 0.18 0.00 0.32 0.16 0.54 0.60 0.60 0.59 0.61 0.05 0.12 0.119
Earnings Stability — — — — — — — 0.78 0.76 0.82 1.00 0.67 0.62 0.52 0.45 0.00 0.02 0.17 0.17 0.02 0.020
Margin Stability — — — — — — — — — — 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Rev. Growth Consistency 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence — — — — — — — 0.99 1.00 0.98 0.97 0.99 1.00 0.97 0.50 0.50 0.50 0.50 0.50 0.50 0.500
Earnings Smoothness — — — — — — — — — — — — — — — — — — — — —
ROE Trend — — — — — — — -0.32 -0.34 -0.43 -0.38 -0.16 -0.18 -0.20 0.51 0.44 0.48 0.70 0.01 -0.12 -0.121
Gross Margin Trend — — — — — — — — — — -30.61 -20.87 -2.41 10.90 16.93 11.62 9.79 10.51 — — —
FCF Margin Trend — — — — — — — — — — -47.77 -29.97 -18.18 7.69 46.40 37.37 40.98 30.25 — — —
Sustainable Growth Rate — — — — — — — — — — — — — — — — — — — — —
Internal Growth Rate — — — — — — — — — — — — — — — — — — — — —
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.86 0.86 -0.17 -0.10 -0.10 -0.11 0.82 0.75 0.66 0.65 0.67 0.74 0.86 0.87 5.22 4.93 4.23 10.85 0.88 0.79 0.790
FCF/OCF 1.62 1.64 -1.37 -2.65 -2.26 -1.18 1.31 1.27 1.22 1.16 1.10 1.05 1.01 1.00 1.00 1.00 1.01 1.01 1.01 1.02 1.021
FCF/Net Income snapshot only 0.806
CapEx/Revenue — — 44.6% 19.1% 8.8% 5.9% 5.4% 5.6% 7.6% 6.1% 6.8% 2.5% 36.5% 2.3% 0.3% 0.3% 0.6% 0.8% — — —
CapEx/Depreciation snapshot only 0.184
Accruals Ratio -0.01 -0.02 -0.25 -0.26 -0.29 -0.31 -0.05 -0.07 -0.10 -0.11 -0.11 -0.08 -0.05 -0.05 0.28 0.26 0.27 0.33 -0.04 -0.08 -0.081
Sloan Accruals snapshot only -0.158
Cash Flow Adequacy snapshot only -48.456
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — — — — — — — — — — — — —
FCF Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Total Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -16.2% -25.6% -34.6% -5.5% -4.7% -9.1% -0.4% -0.4% -0.8% -0.3% -7.0% -35.7% -51.6% -93.9% -1.4% -0.4% -1.1% -0.2% -64.8% -0.2% -0.16%
Total Shareholder Return -16.2% -25.6% -34.6% -5.5% -4.7% -9.1% -0.4% -0.4% -0.8% -0.3% -7.0% -35.7% -51.6% -93.9% -1.4% -0.4% -1.1% -0.2% -64.8% -0.2% -0.16%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.01 1.02 1.02 1.01 1.01 1.00 0.99 1.01 1.09 1.08 1.07 0.99 1.00 1.00 0.999
Interest Burden (EBT/EBIT) 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.09 1.06 1.06 1.05 0.97 0.89 0.90 0.91 0.80 1.00 1.00 1.000
EBIT Margin — — -107.50 -49.51 -26.98 -24.94 -20.82 -27.06 -50.13 -55.53 -91.79 -61.09 -46.31 -19.43 -0.20 -0.21 -0.24 -0.11 — — —
Asset Turnover 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.02 0.35 0.33 0.36 0.38 0.00 0.00 0.000
Equity Multiplier 1.11 1.10 1.42 1.28 1.30 1.32 1.52 1.57 1.65 1.74 1.77 1.77 1.89 2.06 1.59 1.62 1.70 1.80 1.27 1.29 1.293
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.90 $-1.42 $-2.02 $-2.13 $-2.20 $-2.24 $-2.13 $-2.14 $-2.17 $-2.28 $-2.14 $-1.60 $-1.53 $-1.61 $-0.25 $-0.27 $-0.31 $-0.11 $-1.25 $-0.53 $-0.53
Book Value/Share $7.77 $7.27 $6.78 $6.21 $5.70 $5.19 $4.73 $4.18 $3.69 $3.09 $2.86 $2.71 $2.31 $2.05 $2.79 $2.43 $2.04 $1.84 $3.06 $1.13 $1.13
Tangible Book/Share $7.77 $7.27 $6.78 $6.21 $5.70 $5.19 $4.73 $4.18 $3.69 $3.09 $2.86 $2.24 $1.86 $1.62 $2.40 $2.04 $1.64 $1.44 $2.66 $0.96 $0.96
Revenue/Share $0.00 $0.00 $0.02 $0.04 $0.08 $0.09 $0.10 $0.08 $0.04 $0.04 $0.02 $0.02 $0.03 $0.08 $1.33 $1.32 $1.31 $1.26 $0.00 $0.00 $0.00
FCF/Share $-1.26 $-2.02 $-0.48 $-0.59 $-0.49 $-0.28 $-2.28 $-2.05 $-1.75 $-1.70 $-1.58 $-1.25 $-1.34 $-1.40 $-1.33 $-1.33 $-1.30 $-1.21 $-1.11 $-0.43 $-0.43
OCF/Share $-0.78 $-1.23 $0.35 $0.22 $0.22 $0.24 $-1.74 $-1.61 $-1.43 $-1.48 $-1.43 $-1.19 $-1.32 $-1.40 $-1.33 $-1.33 $-1.30 $-1.20 $-1.09 $-0.42 $-0.42
Cash/Share $5.42 $4.09 $6.33 $6.57 $6.14 $5.41 $4.29 $2.64 $2.85 $2.88 $3.08 $2.39 $2.34 $2.41 $1.92 $1.81 $1.54 $1.35 $1.56 $0.58 $0.58
EBITDA/Share $-0.86 $-1.33 $-1.91 $-2.01 $-2.05 $-2.07 $-1.91 $-1.89 $-1.89 $-1.87 $-1.80 $-1.35 $-1.31 $-1.46 $-0.11 $-0.13 $-0.16 $0.01 $-1.10 $-0.49 $-0.49
Debt/Share $0.46 $0.46 $0.44 $0.72 $0.82 $0.85 $0.89 $0.71 $0.80 $0.80 $0.75 $0.69 $0.64 $0.68 $0.61 $0.60 $0.52 $0.50 $0.55 $0.17 $0.17
Net Debt/Share $-4.95 $-3.63 $-5.89 $-5.85 $-5.32 $-4.56 $-3.40 $-1.93 $-2.05 $-2.08 $-2.34 $-1.71 $-1.69 $-1.72 $-1.31 $-1.21 $-1.02 $-0.85 $-1.00 $-0.41 $-0.41
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 0.592
Altman Z-Prime snapshot only -0.014
Piotroski F-Score 2 2 3 3 3 3 2 2 1 1 3 2 4 4 2 3 2 3 2 2 2
Beneish M-Score — — — — — — -2.28 72.01 56.18 -3.46 -5.52 2.34 -80.85 -34.35 112.05 — — — — — —
Ohlson O-Score snapshot only -4.201
ROIC (Greenblatt) snapshot only -69.66%
Net-Net WC snapshot only $0.34
EVA snapshot only $-103049480.00
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only BB+
Credit Score 59.46 61.07 45.19 40.16 40.81 36.64 33.15 33.10 32.10 31.97 32.18 43.07 43.09 36.68 42.79 43.07 42.75 32.40 44.29 48.82 48.822
Credit Grade snapshot only 11
Credit Trend snapshot only 5.747
Implied Spread (bps) snapshot only 400.000
Industry Credit Rank snapshot only 46
Sector Credit Rank snapshot only 42

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms